CytoSorbents

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CytoSorbents reports growth in treatments and sales despite margin challenges

CytoSorbents demonstrated strong performance in treatment deliveries and sales momentum, despite margin challenges.
The company's focus on R&D and regulatory expertise positions it well for future growth opportunities.
Operational improvements and market expansion efforts are key to overcoming current challenges and driving profitability.
With a favorable competitive position and strategic initiatives, CytoSorbents aims to capitalize on emerging market opportunities.

CytoSorbents reports robust Q1 performance and eyes market expansion

CytoSorbents demonstrated strong performance in Q1 2023 with notable revenue and treatment milestones, alongside strategic market expansion efforts.
While facing challenges such as declining gross margins and managing costs, the company is focused on leveraging opportunities for growth and profitability.
Overall, CytoSorbents' financial health, product advancements, and market strategies position it well for future success and market expansion.

CytoSorbents reports robust Q2 earnings, eyes U.S. market expansion

CytoSorbents' Q2 2023 performance reflects strong revenue growth, operational milestones, and strategic partnerships driving future expansion.
While facing challenges in managing cash burn and regulatory hurdles, the company is well-positioned to capitalize on market opportunities.
With a focus on product innovation, market expansion, and financial sustainability, CytoSorbents aims to drive continued growth and market success.

CytoSorbents excels in Q3, eyes FDA approval and market expansion

CytoSorbents reported strong financial performance in Q3 2023, with revenue growth and a robust gross margin.
The company's focus on critical care markets and progress in the STAR-T trial indicate promising growth potential.
Challenges lie in maintaining cash reserves, securing FDA approvals, and navigating market competition.
Opportunities include expanding product portfolio, exploring capital sources, and leveraging favorable market conditions in Canada.

CytoSorb reports revenue growth and margin improvement in 2023

CytoSorb showed solid performance in 2023 with revenue growth and margin improvement.
Strategic partnerships and government support position the company for future growth.
Challenges include distributor order delays and market uncertainties in Germany.
Opportunities lie in new product initiatives, regulatory submissions, and international expansion.

CytoSorbents reports robust Q1 performance, eyes FDA submissions for growth

CytoSorbents delivered strong financial and operational performance in Q1 2024, driven by revenue growth and improved margins.
While facing challenges such as lower grant income and the need to maintain consistent performance, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, market expansion, and financial prudence, CytoSorbents aims to sustain its positive momentum throughout the year.

CytoSorbents reports revenue growth and operational improvements in Q2 2024

CytoSorbents' Q2 2024 showed positive revenue growth, operational improvements, and strategic advancements.
The company's focus on financial stability, regulatory progress, and cost efficiency bodes well for future performance.
While challenges like operational losses and regulatory hurdles persist, opportunities for growth and optimization are evident.
Overall, CytoSorbents is positioned for continued growth and success with a solid financial foundation and strategic direction.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.

PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio.

CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

Cytosorbents Corporation (NASDAQ:CTSO ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Adanna Alexander - IR Phillip Chan - CEO & Director Peter Mariani - CFO Conference Call Participants Tom Kerr - Zacks Small-Cap Research Operator Thank you for standing by. My name is Catherine, and I will be your conference operator today.

Cytosorbents Corporation (CTSO) Q3 2024 Earnings Call Transcript

CytoSorbents files for FDA De Novo marketing approval of DrugSorb-ATR to reduce the severity of CABG-related bleeding due to the blood thinner ticagrelor

CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update

PRINCETON, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that the Dr. Phillip Chan, Chief Executive Officer, and Peter J. Mariani, Chief Financial Officer will be attending and presenting at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 at the Lotte New York Palace Hotel in New York, NY.

CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference

PRINCETON, N.J., Aug. 16, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that it granted inducement equity awards on August 14, 2024 (the “Grant Date”) to its newly-hired Chief Financial Officer, Peter J. Mariani.

CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytosorbents Corporation (NASDAQ:CTSO ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Eric Ribner - IR Phillip Chan - CEO Kathleen Bloch - CFO Vincent Capponi - President & COO Makis Deliargyris - Chief Medical Officer Peter Mariani - CFO Conference Call Participants Michael Sarcone - Jefferies Yuan Zhi - B. Riley Securities Tom Kerr - Zacks Investment Research Sean Lee - H.C.

Cytosorbents Corporation (CTSO) Q2 2024 Earnings Call Transcript

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended June 30, 2024.

CytoSorbents Reports Second Quarter 2024 Financial and Operational Results

PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces the appointment of Peter J.

CytoSorbents Appoints Peter J. Mariani Chief Financial Officer

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2024 operating and financial results after the market close on Tuesday, August 13, 2024.

CytoSorbents to Report Second Quarter 2024 Operating and Financial Results

PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announces that it has regained compliance with the Nasdaq Stock Market's minimum bid price requirement of $1.00 per share.

CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement

PRINCETON, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of deadly conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, is proud to announce the launch of its newly redesigned and consolidated website at www.cytosorbents.com.

CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website

CytoSorbents CEO Dr. Phillip Chan to highlight its innovative critical care and cardiac surgery blood purification therapy at AAPI Conference this weekend

CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress

PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced that on June 28, 2024, the Company entered into a new $20 million credit facility with Avenue Capital Group, including its Avenue Venture Opportunities Fund, L.P.

CytoSorbents Secures $20 Million Credit Facility

PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it will host its 2024 Virtual Annual Stockholders Meeting tomorrow, June 6, 2024 at 10 AM EDT.

CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting

Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Eric Ribner - Investor Relations Phil Chan - Chief Executive Officer Vincent Capponi - President and Chief Operating Officer Kathleen Bloch - Chief Financial Officer Makis Deliargyris - Chief Medical Officer Christian Steiner - Executive Vice President, Sales and Marketing Christopher Cramer - Senior Vice President, Business Development Conference Call Participants Yuan Zhi - B. Riley Securities Sean Lee - H.C.

Cytosorbents Corporation (CTSO) Q1 2024 Earnings Call Transcript

Product Sales up a robust 14% over prior year, and a significant 22% sequentially We believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients On track for U.S. Food and Drug Administration (FDA) De Novo and Health Canada submissions for DrugSorb®-ATR in Q3 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood purification technologies, today reported unaudited financial and operating results for the quarter ended March 31, 2024.

CytoSorbents Reports First Quarter 2024 Results

PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2024 operating and financial results after the market close on Thursday, May 9th, 2024.

CytoSorbents to Report First Quarter 2024 Operating and Financial Results

PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that topline results from its pivotal U.S. and Canadian Safe and Timely Antithrombotic Removal of Ticagrelor (STAR-T) randomized controlled trial will be featured as a late-breaking clinical trial presentation at the 104th Annual Meeting of the American Association for Thoracic Surgery (AATS), taking place Friday, April 26 through Tuesday, April 30, 2024 in Toronto, ON, Canada.Details of the STAR-T presentation are as follows: 104 th American Association for Thoracic Surgery Annual Meeting Session: Adult Cardiac Scientific Session: Trials and Trends Title: A Pivotal Randomized, Sham-controlled Trial Examining the Safety And Efficacy of Intraoperative Removal of Ticagrelor In Patients Undergoing Urgent Cardiac Surgery Presenter: Michael J.

STAR-T Pivotal Trial Results to Be Featured as a Late-Breaking Presentation at the 2024 American Association for Thoracic Surgery Annual Meeting

CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript

STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents intends to submit DrugSorb-ATR for regulatory approval to U.S. Food & Drug Administration (FDA) and Health Canada this year CytoSorb core sales increased approximately 10% year-over-year    2023 Product gross margins increased to 72%    Cumulative CytoSorb treatments surpassed 228,000 PRINCETON, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported financial and operating results for the quarter and year ended December 31, 2023 and provides its 2024 outlook.

CytoSorbents Reports Fourth Quarter and Full Year 2023 Results

PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fiscal 2023 financial results on Thursday, March 14th, 2024 at 4:30PM EDT.

CytoSorbents to Report Fiscal 2023 Operating and Financial Results

PRINCETON, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that Dr. Phillip Chan, Chief Executive Officer, will present at the TD Cowen 44 th Annual Health Care Conference at the Boston Marriott Copley Place, in Boston, MA on Wednesday, March 6th, 2024.

CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference

NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO

CytoSorb Blood Purification Results in Significant Decrease in Organ Failure and Dysfunction in Groundbreaking Heart Transplant Randomized Controlled Trial

Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients

PRINCETON, N.J., Dec. 28, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announces an update on the initial data analysis of primary safety and effectiveness endpoints and the final independent Data and Safety Monitoring Board (“DSMB”) analysis for the pivotal U.S. and Canadian STAR-T (Safe and Timely Antithrombotic Removal of Ticagrelor) randomized controlled trial.

News for CytoSorbents Stock (CTSO)